argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline

Argenx Secures Promising Autoimmune Drug In Forte Biosciences Takeover - argenx (NASDAQ:ARGX), Forte Bios

Argenx is acquiring Forte Biosciences in a $2.2 billion all-cash deal. The $77 per share buyout expands its autoimmune drug portfolio.